This website uses cookies. By using the site you are agreeing to our Privacy Policy.

Japan

Please note that the contents in this webpage  are current as of the date of the announcement and the information including but not limited to the product availability, specification, prices, contacts, are subject to change without prior notice.

Feb 14, 2023
Fujifilm Announces the Start of a New Phase III Clinical Trial in Japan Targeting Patients with Meniscus Injuries
News Release Research & Development
Dec 26, 2022
Fujifilm and Utilization of Carbon Dioxide Institute sign a joint research agreement to develop technology toward decarbonized society
News Release Research & Development Sustainability
Oct 14, 2022
FUJIFILM Toyama Chemical discontinues development of “Avigan® Tablet” anti-influenza drug as a treatment for COVID-19
News Release Research & Development
Jun 1, 2022
Fujifilm Begins U.S. Clinical Phase 2a Study of FF-10832 in Combination with KEYTRUDA® (pembrolizumab, Merck & Co., Inc., Rahway, N.J., U.S.A.) for Patients with Advanced Solid Tumors
News Release Research & Development
Apr 13, 2022
Fujifilm and National Center of Neurology and Psychiatry announce positive study results of Fujifilm’s AI technology predicting mild cognitive impairment conversion to Alzheimer’s disease
News Release Research & Development
Mar 11, 2022
Fujifilm to terminate the enrollment of subjects in the phase III clinical trial of anti-influenza drug Avigan® Tablet in Japan, targeting COVID-19 patients
News Release Research & Development
May 18, 2021
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
News Release Research & Development
Apr 21, 2021
Fujifilm announces the Start of a New Phase III Clinical Trial of Anti-influenza Drug Avigan® Tablet in Japan, Targeting COVID-19 Patients
News Release Research & Development